The EGF A61G Polymorphism Is Associated with Disease-Free Period and Survival in Malignant Melanoma
- 1 October 2006
- journal article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 126 (10) , 2242-2246
- https://doi.org/10.1038/sj.jid.5700377
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Role of Epidermal Growth Factor Receptor Signaling in RAS-Driven MelanomaMolecular and Cellular Biology, 2005
- Sentinel node status in melanoma patients is not predicitive for overall survival upon multivariate analysisBritish Journal of Cancer, 2005
- Epidermal Growth Factor Gene (EGF) Polymorphism and Risk of Melanocytic NeoplasiaJournal of Investigative Dermatology, 2004
- The Relationship Between the Epidermal Growth Factor (EGF) 5′UTR Variant A61G and Melanoma/Nevus SusceptibilityJournal of Investigative Dermatology, 2004
- EGF Gene Polymorphism and the Risk of Incident Primary MelanomaCancer Research, 2004
- EGF +61 gene polymorphism and susceptibility to and prognostic markers in cutaneous malignant melanomaInternational Journal of Cancer, 2003
- The new melanoma staging systemSeminars in Cutaneous Medicine and Surgery, 2003
- Prospective Evaluation of a Follow-Up Schedule in Cutaneous Melanoma Patients: Recommendations for an Effective Follow-Up StrategyJournal of Clinical Oncology, 2003
- Association between functional polymorphism in EGF gene and malignant melanomaThe Lancet, 2002
- Final Version of the American Joint Committee on Cancer Staging System for Cutaneous MelanomaJournal of Clinical Oncology, 2001